



September 19, 2023

## PDAB is recruiting for a clinician to serve on the board

The Prescription Drug Affordability Board is seeking applicants with a background in clinical medicine to fill a vacancy. **We strongly encourage clinicians from rural Oregon to apply.** The board consists of eight members appointed by the governor and confirmed by the Senate. Members serve four years and can seek reappointment. The purpose of the board is to protect Oregon residents, state and local governments, commercial health plans, health care providers, pharmacies and other stakeholders within the health care system from the high cost of prescription drugs.

Candidates must complete the application **by 5 p.m. Monday October 30, 2023**. Applications are submitted through [Workday](#) and must include the following:

- Uploaded resume (PDF only)
- Uploaded short personal bio (PDF only)
- Responses to the three General Application Question Responses to Background Questions
- Responses to the subsequent Gender Identity, Personal Information, and Public Records Disclosure tasks that come up directly after you submit your application

**Residency and background requirements:** Board members must be residents of this state with expertise in health care economics and clinical medicine. Members may not be an employee of, a board member of, or a consultant to a manufacturer or a trade association of manufacturers.

**Time Commitment:** The time commitment is about 10 hours per month. This include two-hour board meetings held on the third Wednesday of the month virtually using Zoom platform.

**Board functions:** Based on information provided to the board from the Drug Pricing Transparency (DPT) program, the board will identify nine drugs and at least one insulin product that may create affordability challenges for patients or health care systems in Oregon. The criteria is based on the board's founding legislation, Senate Bill 844. The board also provides annual reports to the Oregon Legislature with recommendations for ways to lower prescription drug costs. Some of those recommendations were incorporated into Senate Bill 192, passed in 2023. The new law requires board members to provide a report about setting upper payment limits, among other board tasks through 2024.

**Conflict of interest:** Board members sign a conflict of interest form annually. Board members recuse themselves from decisions relating to a prescription drug if the member or their immediate family has received a financial benefit deriving from the result or finding of a study, review or determination by or for the board. Board members declare any real or perceived conflicts of interest at the beginning of each board meeting.

For information about applying for board appointment, please contact Ralph Magrish, Executive Director, Oregon Prescription Drug Affordability Board & Drug Price Transparency Program, [Ralph.M.Magrish@dcbs.oregon.gov](mailto:Ralph.M.Magrish@dcbs.oregon.gov) or 971-375-7591.